Författad vid avdelningen Strategiska vårdgivarfrågor, Region Stockholm
Reviderat datum
2017-12-21
[Helena Ramström 2017-12-21] Ixekizumab is a monoclonal anti-human Interleukin-17A antibody and therefore in accordance with the CHMP guideline on the environmental risk assessment (EMEA/CHMP/SWP/4447/00) is exempt of the need for an environmental risk assessment.